About Health Enhancement Products (OTCMKTS:ZIVO)
Zivo Bioscience, Inc., together with its subsidiaries, focuses on the research and identification of natural bioactive ingredients derived from its proprietary algal cultures. The company intends to license and sell its natural bioactive ingredients to animal, food, dietary supplement, and medical food manufacturers; and license its bioactive molecules as lead compounds or templates for synthetic variants intended for therapeutic applications. It is also involved in developing, manufacturing, marketing, and selling tests that allow individuals to optimize their health and identify future health risks, as well as provides insurers, employers, and healthcare providers with timely information to intervene with wellness programs, fitness regimes, or other preventative measures. The company was formerly known as Health Enhancement Products, Inc. and changed its name to Zivo Bioscience, Inc. in November 2014. Zivo Bioscience, Inc. is headquartered in Keego Harbor, Michigan.
Industry, Sector and Symbol
Industry Food & kindred products
Trailing P/E RatioN/A
Forward P/E RatioN/A
Sales & Book Value
Price / SalesN/A
Price / CashN/A
Book Value($0.12) per share
Price / Book-0.79
EPS (Most Recent Fiscal Year)N/A
Return on EquityN/A
Return on Assets-568.27%
Health Enhancement Products (OTCMKTS:ZIVO) Frequently Asked Questions
What is Health Enhancement Products' stock symbol?
Health Enhancement Products trades on the OTCMKTS under the ticker symbol "ZIVO."
Who are some of Health Enhancement Products' key competitors?
Some companies that are related to Health Enhancement Products include Innovus Pharmaceuticals (INNV), AEterna Zentaris (AEZS), Concordia International (CXRX), Interpace Diagnostics Gr (IDXG), AIT Therapeutics (AITB), Neuralstem (CUR), Tonix Pharmaceuticals (TNXP), Akers Biosciences (AKR), IntelliPharmaCeutics Intl (IPCI), Dynatronics (DYNT), Aradigm (ARDM), Oncobiologics (ONS), Regenerx Biopharmaceuticals (RGRX), Akari Therapeutics (AKTX), ContraVir Pharmaceuticals (CTRV), DelMar Pharmaceuticals (DMPI), Valeritas (VLRX) and AmpliPhi Biosciences (APHB).
Who are Health Enhancement Products' key executives?
Health Enhancement Products' management team includes the folowing people:
- Mr. Philip M. Rice II, Chairman & CFO (Age 63)
- Mr. Andrew A. Dahl, Pres & CEO (Age 64)
- Dr. Scott M. Freeman M.D., Chief Science Officer (Age 61)
- Dr. Amy Elizabeth Steffek Ph.D., Medical Director of R&D
Has Health Enhancement Products been receiving favorable news coverage?
News articles about ZIVO stock have been trending somewhat positive on Sunday, Accern Sentiment reports. The research group scores the sentiment of press coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Health Enhancement Products earned a news impact score of 0.15 on Accern's scale. They also assigned media headlines about the biotechnology company an impact score of 45.30 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the immediate future.
How do I buy shares of Health Enhancement Products?
Shares of ZIVO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Health Enhancement Products' stock price today?
One share of ZIVO stock can currently be purchased for approximately $0.0950.
How big of a company is Health Enhancement Products?
Health Enhancement Products has a market capitalization of $13.41 million. Health Enhancement Products employs 5 workers across the globe.
How can I contact Health Enhancement Products?
Health Enhancement Products' mailing address is 2804 ORCHARD LAKE ROAD SUITE 202, KEEGO HARBOR MI, 48320. The biotechnology company can be reached via phone at 248-452-9866 or via email at [email protected]
MarketBeat Community Rating for Health Enhancement Products (ZIVO)MarketBeat's community ratings are surveys of what our community members think about Health Enhancement Products and other stocks. Vote "Outperform" if you believe ZIVO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ZIVO will underperform the S&P 500 over the long term. You may vote once every thirty days.
Health Enhancement Products (OTCMKTS:ZIVO) Analyst Ratings History
(Data available from 4/22/2016 forward)
Health Enhancement Products (OTCMKTS:ZIVO) Dividend History by Quarter
(Data available from 1/1/2013 forward)
|Announced||Period||Amount||Yield||Ex-Dividend Date||Record Date||Payable Date|
Health Enhancement Products (OTCMKTS ZIVO) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 23.90%
Institutional Ownership Percentage: 0.06%
Health Enhancement Products (OTCMKTS ZIVO) Insider Trading History
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
|3/8/2018||Christopher D Maggiore||Director||Buy||116,000||$0.11||$12,760.00|| |
|3/5/2018||Christopher D Maggiore||Director||Buy||60,000||$0.12||$7,200.00|| |
|2/14/2018||Christopher D Maggiore||Director||Buy||116,000||$0.09||$10,440.00|| |
|1/23/2018||Christopher D Maggiore||Director||Buy||74,000||$0.07||$5,180.00|| |
|1/3/2018||Christopher D Maggiore||Director||Buy||103,000||$0.09||$9,270.00|| |
|12/19/2017||Christopher D Maggiore||Director||Buy||125,000||$0.09||$11,250.00|| |
|11/29/2017||Christopher D Maggiore||Director||Buy||197,000||$0.10||$19,700.00|| |
|11/17/2017||Christopher D Maggiore||Director||Buy||20,000||$0.08||$1,600.00|| |
|11/10/2017||Christopher D Maggiore||Director||Buy||93,000||$0.07||$6,510.00|| |
|10/26/2017||Christopher D Maggiore||Director||Buy||50,000||$0.08||$4,000.00|| |
|8/24/2017||Christopher D Maggiore||Director||Buy||20,000||$0.07||$1,400.00||13,602,831|| |
|4/27/2017||Christopher D Maggiore||Director||Buy||114,000||$0.07||$7,980.00||13,443,831|| |
|4/29/2016||Hep Investments Llc||Major Shareholder||Buy||107,064||$0.08||$8,565.12||1,338,628|| |
|4/28/2015||Hep Investments Llc||Major Shareholder||Buy||299,400||$0.13||$38,922.00|| |
|1/6/2015||Christopher D Maggiore||Director||Buy||39,069||$0.09||$3,516.21|| |
|5/9/2014||Christopher D Maggiore||Major Shareholder||Buy||47,400||$0.17||$8,058.00|| |
|5/2/2014||Christopher D Maggiore||Major Shareholder||Buy||225,000||$0.18||$40,500.00|| |
|4/23/2014||Christopher D Maggiore||Major Shareholder||Buy||109,769||$0.19||$20,856.11|| |
|8/1/2013||Christopher D Maggiore||Major Shareholder||Buy||833,333||$0.12||$99,999.96|| |
|4/19/2013||Christopher D Maggiore||Major Shareholder||Buy||67,700||$0.38||$25,726.00|| |
|4/12/2013||Christopher D Maggiore||Major Shareholder||Buy||8,200||$0.30||$2,460.00|| |
|4/1/2013||Christopher D Maggiore||Major Shareholder||Buy||37,000||$0.31||$11,470.00|| |
|3/25/2013||Christopher D Maggiore||Major Shareholder||Buy||155,200||$0.29||$45,008.00|| |
|3/8/2013||Christopher D Maggiore||Major Shareholder||Buy||201,000||$0.23||$46,230.00|| |
|2/28/2013||Christopher D Maggiore||Major Shareholder||Buy||25,500||$0.22||$5,610.00|| |
|2/22/2013||Christopher D Maggiore||Major Shareholder||Buy||118,400||$0.23||$27,232.00|| |
|2/11/2013||Christopher D Maggiore||Major Shareholder||Buy||20,000||$0.24||$4,800.00|| |
|2/8/2013||Christopher D Maggiore||Major Shareholder||Buy||50,600||$0.24||$12,144.00|| |
|1/29/2013||Christopher D Maggiore||Major Shareholder||Buy||87,500||$0.27||$23,625.00|| |
|1/25/2013||Christopher D Maggiore||Major Shareholder||Buy||201,125||$0.26||$52,292.50|| |
|1/22/2013||Christopher D Maggiore||Major Shareholder||Buy||16,000||$0.25||$4,000.00|| |
|1/18/2013||Christopher D Maggiore||Major Shareholder||Buy||18,500||$0.25||$4,625.00|| |
|1/15/2013||Christopher D Maggiore||Major Shareholder||Buy||52,500||$0.26||$13,650.00|| |
|1/14/2013||Christopher D Maggiore||Major Shareholder||Buy||60,000||$0.26||$15,600.00|| |
|1/11/2013||Christopher D Maggiore||Major Shareholder||Buy||37,500||$0.28||$10,500.00|| |
|1/10/2013||Christopher D Maggiore||Major Shareholder||Buy||163,000||$0.27||$44,010.00|| |
|11/28/2012||Andrew A Dahl||CEO||Buy||5,000||$0.11||$550.00|| |
|11/27/2012||Andrew A Dahl||CEO||Buy||95,000||$0.11||$10,450.00|| |
Health Enhancement Products (OTCMKTS ZIVO) News Headlines
|Ubiquitech Reports 2018 First Quarter Earnings Increase of 33.3% to $151,870 from the Previous Year on Revenues of $1,025,894|
globenewswire.com - April 19 at 10:29 AM
|UnitedHealth Group Reports First Quarter Results|
www.bizjournals.com - April 17 at 10:49 AM
|What caffeine does to your body and brain|
www.msn.com - April 17 at 10:49 AM
|Apotheca Biosciences (PCFP) R & D Focuses on Opioid Crisis, a National Public Health Emergency|
globenewswire.com - April 17 at 10:49 AM
|OP company recalls male supplement for containing actual drugs|
www.bizjournals.com - April 17 at 10:49 AM
|ZIVO Bioscience, Inc. Welcomes New Vice-President of Research & Development|
finance.yahoo.com - March 29 at 10:54 AM
|Zivo Bioscience Inc (ZIVO) Director Buys $12,760.00 in Stock|
www.americanbankingnews.com - March 12 at 5:14 PM
|Zivo Bioscience Inc (ZIVO) Director Buys $10,440.00 in Stock|
www.americanbankingnews.com - February 14 at 10:18 PM
|Largest Shareholder of ZIVO Bioscience, Inc. to extend maturity date of its Convertible Debt|
finance.yahoo.com - February 13 at 8:24 AM
|BRIEF-Zivo Bioscience And Tianjin Norland Biotech Execute LOI To Produce Zivo Algae Strain In China|
www.reuters.com - February 1 at 5:08 PM
|ZIVO Bioscience and Tianjin Norland Biotech Execute Letter of Intent to Produce ZIVO Algae Strain in China for International and Domestic Markets|
finance.yahoo.com - February 1 at 8:29 AM
|ZIVO Bioscience Subsidiary Wellmetris Selected to Present at Biotech Showcase During JPMorgan Healthcare Conference Jan 7-10 in San Francisco, CA|
finance.yahoo.com - January 8 at 10:42 AM
|Insider Buying: Zivo Bioscience Inc (ZIVO) Director Purchases 125,000 Shares of Stock|
www.americanbankingnews.com - December 20 at 2:28 PM
|ZIVO Bioscience, Inc. (ZIVO) Director Purchases $19,700.00 in Stock|
www.americanbankingnews.com - November 29 at 8:48 PM
|ZIVO Bioscience, Inc. Annual Shareholder Meeting and Conference Call Slated for November 8, 2017 in Detroit, Michigan|
finance.yahoo.com - November 7 at 4:20 PM
|ZIVO Bioscience and NutriQuest LLC Conclude Two Poultry Studies With Positive Results, Continue to Move Forward With FDA Compliance|
finance.yahoo.com - September 19 at 10:01 AM
|ZIVO Bioscience, Inc. Kicks Off Final Phase of Bovine Mastitis Study|
finance.yahoo.com - September 11 at 8:58 AM
|ZIVO Bioscience, Inc. Enters Into Pilot Program to Expand Production Into Europe, Contracts With Algatek Asturias, S.L.|
finance.yahoo.com - July 11 at 9:54 AM
|BRIEF-Zivo Bioscience executes debt restructuring|
www.businessinsider.com - March 7 at 8:01 AM
|ZIVO BIOSCIENCE, INC. Files SEC form 8-K, Regulation FD Disclosure|
biz.yahoo.com - December 16 at 6:39 AM
|ZIVO BIOSCIENCE, INC. Files SEC form 8-K, Financial Statements and Exhibits|
biz.yahoo.com - January 7 at 3:15 PM
|ZIVO BIOSCIENCE, INC. Files SEC form 10-Q, Quarterly Report|
biz.yahoo.com - November 13 at 12:38 PM
|ZIVO BIOSCIENCE, INC. Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Submission|
biz.yahoo.com - June 29 at 3:38 PM
|ZIVO BIOSCIENCE, INC. Files SEC form 8-K, Other Events|
biz.yahoo.com - June 23 at 5:24 PM
|ZIVO BIOSCIENCE, INC. Files SEC form 10-K, Annual Report|
biz.yahoo.com - April 6 at 3:22 PM
|ZIVO BIOSCIENCE, INC. Files SEC form 8-K, Creation of a Direct Financial Obligation or an Obligation under an Off-Bal|
biz.yahoo.com - December 29 at 1:37 PM
Health Enhancement Products (OTCMKTS:ZIVO) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Financials are not available for this stock.
Health Enhancement Products (OTCMKTS ZIVO) Stock Chart for Sunday, April, 22, 2018